DermatologyInvestigational

Rigin (Palmitoyl Tetrapeptide-7)

Topical

Overview

Rigin is a lipopeptide composed of the tetrapeptide sequence Gly-Gln-Pro-Arg conjugated to palmitic acid. It is designed to reduce production of interleukin-6 and other pro-inflammatory cytokines in dermal fibroblasts, thereby mitigating chronic low-grade inflammation associated with skin aging.

Mechanism of Action

By modulating the inflammatory microenvironment, the peptide is proposed to support matrix integrity and reduce glycation-induced damage..

Research Summary & Key Findings

In vitro studies using UV-irradiated or cytokine-stimulated fibroblasts have demonstrated that palmitoyl tetrapeptide-7 reduces IL-6 secretion and restores collagen synthesis. Industry-sponsored trials, often in combination with palmitoyl tripeptide-1 (Matrixyl 3000), have reported improvements in skin firmness and wrinkle depth, though isolated effects of Rigin are not well characterized. Independent peer-reviewed clinical data remain limited.

Clinical Status

Investigational

Rigin (Palmitoyl Tetrapeptide-7) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Topical

Related Peptides in Dermatology

Find a Provider

Find a verified provider who offers Rigin (Palmitoyl Tetrapeptide-7) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Rigin (Palmitoyl Tetrapeptide-7).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.